GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Radient Technologies Inc (OTCPK:RDDTF) » Definitions » 5-Year ROIIC %

Radient Technologies (Radient Technologies) 5-Year ROIIC % : 0.00% (As of Mar. 2022)


View and export this data going back to 2016. Start your Free Trial

What is Radient Technologies 5-Year ROIIC %?

5-Year Return on Invested Incremental Capital (5-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 5-year. Radient Technologies's 5-Year ROIIC % for the quarter that ended in Mar. 2022 was 0.00%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for Radient Technologies's 5-Year ROIIC % or its related term are showing as below:

RDDTF's 5-Year ROIIC % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 3.435
* Ranked among companies with meaningful 5-Year ROIIC % only.

Radient Technologies 5-Year ROIIC % Historical Data

The historical data trend for Radient Technologies's 5-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Radient Technologies 5-Year ROIIC % Chart

Radient Technologies Annual Data
Trend Dec13 Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22
5-Year ROIIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -246.18 -34.43 -26.88 -6.69

Radient Technologies Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
5-Year ROIIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -6.69 - - -

Competitive Comparison of Radient Technologies's 5-Year ROIIC %

For the Drug Manufacturers - Specialty & Generic subindustry, Radient Technologies's 5-Year ROIIC %, along with its competitors' market caps and 5-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Radient Technologies's 5-Year ROIIC % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Radient Technologies's 5-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where Radient Technologies's 5-Year ROIIC % falls into.



Radient Technologies 5-Year ROIIC % Calculation

Radient Technologies's 5-Year ROIIC % for the quarter that ended in Mar. 2022 is calculated as:

5-Year ROIIC %=5-Year Incremental Net Operating Profit After Taxes (NOPAT)**/5-Year Incremental Invested Capital**
=( -5.221 (Mar. 2022) - -3.028 (Mar. 2017) )/( 35.264 (Mar. 2022) - 4.791 (Mar. 2017) )
=-2.193/30.473
=-7.20%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Annual data of NOPAT and Invested Capital was used to calculate 5-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Radient Technologies  (OTCPK:RDDTF) 5-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


Radient Technologies 5-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of Radient Technologies's 5-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Radient Technologies (Radient Technologies) Business Description

Traded in Other Exchanges
N/A
Address
4035 101 St. NW, Edmonton, AB, CAN, T6E 0A4
Radient Technologies Inc is a Canadian company engaged in manufacturing cannabis derivatives, formulations, and products. It has developed its extraction process, Microwave Assisted Processing (MAP), which is used for producing a consistent product at industrial-scale quantities. It provides its customers and partners with white-label extracts, formulations, and finished products that contain a broad spectrum of cannabinoid and terpene profiles. While it operates in Canada and is building an additional facility in Germany. It operates in a single segment namely the production and sale of cannabis-related retail products.

Radient Technologies (Radient Technologies) Headlines

From GuruFocus

Radient Technologies Inc. Applies to Extend Warrants

By GlobeNewswire GlobeNewswire 03-31-2020